New research shows that young breast cancer patients with high-risk genes may be able to prevent their cancer from returning ...
Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral ...
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to ...
Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral risk-reducing mastectomy (RRM) and/or a risk-reducing ...
Cancer researchers at Fox Chase Cancer Center in Philadelphia see promise in personalized medicine to help crack the code on ...
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median ...
Adjuvant Lynparza remains beneficial for patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer, study results have shown.
Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative ...
Women who underwent bilateral mastectomy or removal of ovaries and Fallopian tubes had lower rates of recurrence, ovarian ...
Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral ...
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median ...
Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral risk-reducing mastectomy (RRM) and/or a risk-reducing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback